Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Inhaled BIBW 2948 BS in Healthy Males
NCT02214901Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Mar 2005
- Primary completion
- Jul 2005
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing BIBW 2948 BS with Placebo (2 arms). Primary endpoints: Changes from baseline in vital signs at 8 days, Changes from baseline in clinical laboratory tests at 8 days and 4 more. Started Mar 2005; status: completed.
02
Drugs
BIBW 2948 BS
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT02214901.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02214901.